MBD2 and colorectal carcinoma: Therefore, targeting MBD2 specifically at its IDPR would be a promising approach to the development of antimetastatic agents by inhibiting its DOT-based PPI with p66α that is essential for the integration of CRC and thus for its critical function in EMT.